Paper8622014
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
Findlay M and 9 others. J Clin Oncol, 1996. Cited by 228 papers, by iCite.
Cite this record
ConductScience Library. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. Papers, record 8622014. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8622014
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antimetabolites, Antineoplastic | Major topic |
| Antineoplastic Agents | Major topic |
| Colorectal Neoplasms | Major topic |
| Deoxyglucose | Major topic |
| Fluorine Radioisotopes | Major topic |
| Fluorouracil | Major topic |
| Interferon-alpha | Major topic |
| Liver Neoplasms | Major topic |
| Tomography, Emission-Computed | Major topic |
| Body Weight | |
| Fluorodeoxyglucose F18 | |
| Humans | |
| Interferon alpha-2 | |
| Recombinant Proteins |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 8622012 | Positron emission tomography in the clinical evaluation of metastatic cancer. | https://conductscience.org/library/papers/8622012 |
Source PubMed
Cited by57
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 228 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42872124 | Integrated Multi-Time-Point 18F-FAPI PET/CT and Immune Histopathology for Predicting Pathological Complete Response in Microsatellite-Stable Locally Advanced Rectal Cancer Treated With Neoadjuvant Radiotherapy, Chemotherapy, and Immunotherapy. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42872124 | PubMed |
| 42230653 | Diagnostic Performance of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Evaluating Neoadjuvant Therapy Pathological Response in Breast Cancer. | NPJ Breast Cancer | 2026 | https://conductscience.org/library/papers/42230653 | PubMed |
| 37589901 | Performance of [18F]FDG PET/CT versus FAPI PET/CT for lung cancer assessment: a systematic review and meta-analysis. | Eur Radiol | 2024 | https://conductscience.org/library/papers/37589901 | PubMed |
| 36920590 | Harmonization of standard uptake values across different positron emission tomography/computed tomography systems and different reconstruction algorithms: validation in oncology patients. | EJNMMI Phys | 2023 | https://conductscience.org/library/papers/36920590 | PubMed |
| 36326867 | [68Ga]Ga-FAPI PET for the evaluation of digestive system tumors: systematic review and meta-analysis. | Eur J Nucl Med Mol Imaging | 2023 | https://conductscience.org/library/papers/36326867 | PubMed |
| 33003615 | 18F-FDG PET/MR versus MR Alone in Whole-Body Primary Staging and Restaging of Patients with Rectal Cancer: What Is the Benefit of PET? | J Clin Med | 2020 | https://conductscience.org/library/papers/33003615 | PubMed |
| 31088837 | Magnetic Resonance Imaging Is More Sensitive Than PET for Detecting Treatment-Induced Cell Death-Dependent Changes in Glycolysis. | Cancer Res | 2019 | https://conductscience.org/library/papers/31088837 | PubMed |
| 28559939 | Comparison of Quantitative Methods on FDG PET/CT for Treatment Response Evaluation of Metastatic Colorectal Cancer. | Nucl Med Mol Imaging | 2017 | https://conductscience.org/library/papers/28559939 | PubMed |
| 28477166 | The accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review. | Eur Radiol | 2017 | https://conductscience.org/library/papers/28477166 | PubMed |
| 27072811 | Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer. | Eur J Nucl Med Mol Imaging | 2016 | https://conductscience.org/library/papers/27072811 | PubMed |
| 26739333 | Imaging metabolic heterogeneity in cancer. | Mol Cancer | 2016 | https://conductscience.org/library/papers/26739333 | PubMed |
| 26589835 | Prognostic significance of (18)FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis. | Cancer Imaging | 2015 | https://conductscience.org/library/papers/26589835 | PubMed |
| 26396634 | Tumor SUVmax Normalized to Liver Uptake on (18)F-FDG PET/CT Predicts the Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. | Nucl Med Mol Imaging | 2014 | https://conductscience.org/library/papers/26396634 | PubMed |
| 26090365 | State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET. | Front Med (Lausanne) | 2015 | https://conductscience.org/library/papers/26090365 | PubMed |
| 25831053 | Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer. | PLoS One | 2015 | https://conductscience.org/library/papers/25831053 | PubMed |
| 25763526 | Diagnostic accuracy of diffusion-weighted magnetic resonance imaging versus positron emission tomography/computed tomography for early response assessment of liver metastases to Y90-radioembolization. | Invest Radiol | 2015 | https://conductscience.org/library/papers/25763526 | PubMed |
| 25481195 | PET scans as a predictive marker of survival in advanced colorectal cancer. | Clin Colorectal Cancer | 2015 | https://conductscience.org/library/papers/25481195 | PubMed |
| 25290692 | Correlation between long-term aspirin use and F-fluorodeoxyglucose uptake in colorectal cancer measured by PET/CT. | PLoS One | 2014 | https://conductscience.org/library/papers/25290692 | PubMed |
| 24905030 | A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer. | Cancer Med | 2014 | https://conductscience.org/library/papers/24905030 | PubMed |
| 24833867 | Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantation. | World J Gastroenterol | 2014 | https://conductscience.org/library/papers/24833867 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IFNA2 | 3440 | PubTator's text mining | https://conductscience.org/library/genes/3440 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8622014
GET https://conductscience.org/api/papers/v1/8622014/cited_by?page=2